Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026909 | 1.00 | SLC6A2 (0.34) | SLC6A2SLC6A4SLC6A3HTR2AHRH1 | |
| SCHEMBL8276606 | 0.87 | TSHR (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22878514 | 0.87 | LMNA (0.40) | SLC6A2SLC6A4SLC6A3TDP1MAPT | |
| SCHEMBL8322058 | 0.87 | TSHR (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14208437 | 0.85 | SLC6A2 (0.34) | SLC6A2SLC6A4 | |
| SCHEMBL13900574 | 0.83 | — | — | |
| SCHEMBL13312874 | 0.83 | — | — | |
| SCHEMBL3656270 | 0.83 | — | — | |
| SCHEMBL8780334 | 0.83 | LMNA (0.41) | LMNA | |
| SCHEMBL8492819 | 0.83 | MAPT (0.35) | HTR2AHRH1TDP1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115624-A1 | BORON COMPOUNDS, RELATED LIPID PARTICLES, LIPOPLEXES, COMPOSITIONS, METHODS OF USE, AND METHODS OF MAKING | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-4514810-A1 | BORON COMPOUNDS, RELATED LIPID PARTICLES, LIPOPLEXES, COMPOSITIONS, METHODS OF USE, AND METHODS OF MAKING | University Of Louisville Research Foundation, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212623-A1 | BORON COMPOUNDS, RELATED LIPID PARTICLES, LIPOPLEXES, COMPOSITIONS, METHODS OF USE, AND METHODS OF MAKING | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-8361779-B2 | Buffer compounds | SACHEM, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120129240-A1 | BUFFER COMPOUNDS | SACHEM, INC. | 2012-05-24 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598421-B2 | Materials for the delivery of biologically-active material to cells | UCL BIOMEDICA PLC (GB) | 2009-10-06 | — | — | US | disclosed |
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | NANOGENICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| EP-1506019-A1 | COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | University College London (GB) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094974-A1 | COMPLEXES FOR THE DELIVERY OF BIOLOGICALLY-ACTIVE MATERIAL TO CELLS | UNIVERSITY COLLEGE LONDON (GB) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245446-A1 | Materials for the delivery of biologically-active material to cells | ITGB1, ITGA2B, ITGB2 | SLC6A2 4020/4885SLC6A4 4198/4885SLC6A3 4327/4885 |
| US-20250115624-A1 | BORON COMPOUNDS, RELATED LIPID PARTICLES, LIPOPLEXES, COMPOSITIONS, METHODS OF USE, AND METHODS OF MAKING | LIPA, LIPC, ABHD16A | SLC6A2 3320/4885SLC6A4 4496/4885SLC6A3 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.